Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.
Wei Xie, Laura Mondragón, Brynjar Mauseth, Yan Wang, Jonathan Pol, Sarah Lévesque, Heng Zhou, Takahiro Yamazaki, J. Johannes Eksteen, Laurence Zitvogel, Baldur Sveinbjørnsson, Øystein Rekdal, Oliver Kepp, Guido Guido Kroemer
Discussion(0)
No comments yet. Be the first to comment.